A 3-year-old with hepatoblastoma — the most common pediatric liver cancer — has achieved complete and lasting remission following treatment with a novel CAR T-cell immunotherapy, according to a new report in the New England Journal of Medicine. The child had already failed three lines of chemotherapy and developed a new lung metastasis after surgery before enrolling in the CARE study (NCT04715191), a first-in-human Phase 1 trial led by researchers at Baylor College of Medicine, Texas Children's Hospital, and Seattle Children's.

The therapy used the patient's own immune cells, engineered to target glypican-3 (GPC3), a protein overexpressed in hepatoblastoma. The CAR T cells were "armed" with immune-boosting cytokines IL-15 and IL-21, plus a built-in safety switch to control cell expansion. Two outpatient infusions, eight weeks apart, converted a partial response into complete disappearance of metastatic disease — with no serious toxicities reported.

Key Takeaways:

• Complete regression has been sustained for over one year post-treatment
• No dose-limiting toxicities or cytokine release syndrome were observed
• The outpatient administration model could broaden access to CAR T therapy for solid tumors
• GPC3 targeting may hold promise across other GPC3-positive solid tumors

Why it matters: CAR T-cell therapy has transformed blood cancers, but success in solid tumors has remained elusive. This case offers a rare proof-of-concept that durable remission in a chemotherapy-resistant pediatric solid tumor is achievable — safely, and without hospitalization.